JB Pharma to Acquire the Entire Razel (Rosuvastatin) Franchise for Rs. 314 Crores
- The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
- Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country
JB Pharma, one of the fastest growing pharmaceutical companies in India, has entered into an agreement with Glenmark Pharmaceuticals Ltd., to acquire the entire Razel (Rosuvastatin) franchise for the India and Nepal region for a whopping Rs. 314 crores. With this acquisition, JB Pharma will complete its cardiac portfolio making it a leader in this segment, as Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country. These brands are focused on the cardiac segment in India and Nepal with a total covered market size of INR 2,444 crores as per IQVIA MAT Oct ’22 numbers.
Commenting on the acquisition, Mr. Nikhil Chopra, CEO & Whole Time Director, JB Pharma said, “We are glad to announce the acquisition of the Razel (Rosuvastatin & combinations) franchise, thereby marking JB’s expansion into Statins, which is the largest therapeutic segment in cardiology. With this addition, we now have established strong position in statins besides being among the leaders in Hypertension and Heart failure – all the fastest growing therapeutic indications in cardiology.”
He further added, “We see good growth potential from the acquired brands. This acquisition will help us leverage our existing Go-To-Market model focussed for this segment and further strengthen our chronic portfolio.”
For more information, visit www.jbpharma.com
